Home > Riviste > Panminerva Medica > Fascicoli precedenti > Panminerva Medica 2018 September;60(3) > Panminerva Medica 2018 September;60(3):101-8

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

REVIEW   

Panminerva Medica 2018 September;60(3):101-8

DOI: 10.23736/S0031-0808.18.03450-X

Copyright © 2018 EDIZIONI MINERVA MEDICA

lingua: Inglese

Alpha1-antitrypsin deficiency: what’s new after European Respiratory Society Statement

Filippo PATRUCCO 1 , Ludovica VENEZIA 2, Francesco GAVELLI 3, Rinaldo PELLICANO 2, Paolo SOLIDORO 1

1 Division of Pulmonology, Cardiothoracic and Vascular Department, AOU Città della Salute e della Scienza, Turin, Italy; 2 General and Specialistic Medical Department, Division of Gastroenterology, AOU Città della Salute e della Scienza, Turin, Italy; 3 Unit of Emergency Medicine, Department of Translational Medicine, AOU Maggiore della Carità of Novara, University of Piemonte Orientale, Novara, Italy


PDF


Alpha-1 antitrypsin deficiency (AATD) is a clinically under-recognized inherited disorder affecting the lungs and the liver. The most common manifestations are pulmonary emphysema, bronchiectasis and liver disease. The recent publication of the European Respiratory Society statement on diagnosis and treatment of pulmonary diseases has replaced the 2003 American Thoracic Society and European Respiratory Society one. New outcome parameters have been introduced and validated by observational and randomized clinical trials, and new information about efficacy and safety of augmentation therapy have been published. In this narrative review we have commented the crucial points of the new European Respiratory Society statement on AATD, including a review of the literature on liver involvement and treatments.


KEY WORDS: Alpha 1-antitrypsin deficiency - Emphysema - Liver diseases

inizio pagina